Hepatitis/MASH

Hepatitis B tends to be more aggressive in HIV patients, increasing the risk of cirrhosis, end-stage liver disease, and hepatocellular cancer.

Antiviral drugs can spare livers for patients with other liver diseases.

Tops news of the day from across the healthcare landscape.

Tops news of the day from across the healthcare landscape.

Coinfection with hepatitis B virus isn't uncommon among those infected with HIV.

A new treatment for hepatitis B significantly reduced viral load in 4 weeks.

A new treatment for hepatitis B significantly reduced viral load in 4 weeks.

Prognostic model provides simple and accurate clinical description for each HCC patient.

Decision will make direct-acting antivirals available to 40% of the state's estimated 60,000 Medicaid patients with chronic HCV.

High prevalence of anti-HIV antibodies found in patients with hepatitis C and hepatitis B.

The right combination of direct acting antiviral drugs is vital for patients with HCV.

Possible link found between an antiviral treatment for HBV and an increased risk of colorectal and cervical cancers.

Patients with HCV genotype 3 without scarred livers achieved SVR after 8 weeks.

Patients with HCV genotype 3 without scarred livers achieved SVR after 8 weeks.

Oregon woman infected with HCV from a blood transfusion was at death’s door until she was cured by Harvoni.

Top news of the day from across the health care landscape.

Oropharyngeal and nonoropharyngeal cancers more prevalent in patients diagnosed with HCV.

Current CDC testing guidelines fall short of solving the problem of undiagnosed patients with hepatitis C.

Patients receiving nucleos(t)ide analogue treatment for HBV have a lower risk of developing hepatocellular carcinoma and cirrhosis.

Researchers explore vaccine to produce simultaneous immune response against hepatitis C and HIV.

Treating hepatitis C could potentially be less expensive with generic treatments.

Treating hepatitis C could potentially be less expensive with generic treatments.

Tenofovir alafenamide found safer than tenofovir disoproxil fumarate in multiple trials.

Overall positive results shown in studies with Harvoni and sofosbuvir/velpatasvir.

Overall positive results shown in studies with Harvoni and sofosbuvir/velpatasvir.